Neonatal sepsis: Pathogenesis and supportive therapy

Bacterial infections remain an important cause of neonatal mortality and morbidity. Pathogenesis of the neonate's predilection to infection are multifactorial. Factors directly attributable to the infant include humoral, phagocytic, and cellular deficiencies. Septic neonates may have reduced ne...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in perinatology 1997-02, Vol.21 (1), p.28-38
Main Author: Wolach, Baruch
Format: Article
Language:English
Subjects:
Antibody Formation
Humans
Immunity, Cellular
Immunoglobulins, Intravenous - therapeutic use
Infant, Newborn
Kinetics
Neutropenia - immunology
Phagocytes - immunology
Randomized Controlled Trials as Topic
Sepsis - etiology
Sepsis - immunology
Sepsis - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bacterial infections remain an important cause of neonatal mortality and morbidity. Pathogenesis of the neonate's predilection to infection are multifactorial. Factors directly attributable to the infant include humoral, phagocytic, and cellular deficiencies. Septic neonates may have reduced neutrophil storage pools that cause profound neutropenia. Both correlate with poor prognosis. Antibiotic administration is mandatory in neonatal sepsis. Supplementary treatments may be useful. Granulocyte transfusions, when available, provide neutrophils, improving the neonate's neutrophil count and neutrophil function. The efficacy of intravenous immunoglobulin (IVIG) is questionable because the prophylactic and therapeutic administration of IVIG fails to reduce the incidence of bacterial infections or affect the overall survival rate. Hyperimmune preparations seem to be more effective. The administration of granulocyte colony-stimulating factor induces myeloid progenitor proliferation, enhances the neutrophil storage pool, produces neutrophilia, and improves neutrophil function. More extensive, well-designed, and carefully control trials are needed to determine the benefit of supportive therapies for neonatal sepsis.
ISSN:0146-0005
1558-075X
DOI:10.1016/S0146-0005(97)80017-1